These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9465320)

  • 21. [Advances in the topical steroid treatment of inflammatory bowel diseases].
    Díaz Blasco J; Robledo Andrés P
    Rev Esp Enferm Dig; 1995 Nov; 87(11):802-7. PubMed ID: 8534536
    [No Abstract]   [Full Text] [Related]  

  • 22. Budesonide modified-release capsules.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
    Naganuma M; Aoyama N; Tada T; Kobayashi K; Hirai F; Watanabe K; Watanabe M; Hibi T
    J Gastroenterol; 2018 Apr; 53(4):494-506. PubMed ID: 28779419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Patients prefer foam].
    MMW Fortschr Med; 2007 May; 149(21):48. PubMed ID: 17668735
    [No Abstract]   [Full Text] [Related]  

  • 25. Topical therapy is underused in patients with ulcerative colitis.
    Seibold F; Fournier N; Beglinger C; Mottet C; Pittet V; Rogler G;
    J Crohns Colitis; 2014 Jan; 8(1):56-63. PubMed ID: 23566922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; Seow CH; Steinhart AH; Griffiths AM
    Cochrane Database Syst Rev; 2010 Oct; (10):CD007698. PubMed ID: 20927762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A safety evaluation of budesonide MMX for the treatment of ulcerative colitis.
    Bezzio C; Festa S; Zerboni G; Papi C; Manes G; Saibeni S
    Expert Opin Drug Saf; 2018 Apr; 17(4):437-444. PubMed ID: 29473429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.
    Naganuma M; Aoyama N; Suzuki Y; Nishino H; Kobayashi K; Hirai F; Watanabe K; Hibi T
    J Crohns Colitis; 2016 Jul; 10(7):828-36. PubMed ID: 26577683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of mild persistent asthma in children.
    Levy ML
    Lancet; 2011 May; 377(9779):1743; author reply 1744. PubMed ID: 21601698
    [No Abstract]   [Full Text] [Related]  

  • 30. Nanotherapeutics for the treatment of inflammatory bowel disease.
    Chen Q; Xiao B; Merlin D
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):495-497. PubMed ID: 28317404
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical effectiveness of various budesonide preparations in Crohn disease].
    Schölmerich J
    Med Klin (Munich); 1999 Feb; 94 Suppl 1():30-8. PubMed ID: 10194946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contact allergy to budesonide and perforation of the nasal septum.
    Isaksson M; Bruze M; Wihl JA
    Contact Dermatitis; 1997 Sep; 37(3):133. PubMed ID: 9330826
    [No Abstract]   [Full Text] [Related]  

  • 33. [Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study].
    Rufle W; Frühmorgen P; Huber W; Kimmig JM
    Z Gastroenterol; 2000 Apr; 38(4):287-93. PubMed ID: 10820860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
    Bischoff A
    MMW Fortschr Med; 2010 Jan; 152(1-2):20. PubMed ID: 20302159
    [No Abstract]   [Full Text] [Related]  

  • 35. Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial.
    Keller R; Stoll R; Foerster EC; Gutsche N; Domschke W
    Aliment Pharmacol Ther; 1997 Dec; 11(6):1047-52. PubMed ID: 9663828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of mizoribine in children with inflammatory bowel disease.
    Fujii T; Ohtsuka Y; Yamakawa Y; Ohtani K; Kudo T; Ohtomo Y; Nagata S; Shimizu T
    Pediatr Int; 2010 Feb; 52(1):e57-9. PubMed ID: 20158652
    [No Abstract]   [Full Text] [Related]  

  • 37. [Budesonide: effective, with low side effects. On the road to new treatment methods in Crohn disease].
    Internist (Berl); 1998 Sep; 39(9 Suppl Auf Dem We):1-8. PubMed ID: 9772715
    [No Abstract]   [Full Text] [Related]  

  • 38. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group.
    Hanauer SB; Robinson M; Pruitt R; Lazenby AJ; Persson T; Nilsson LG; Walton-Bowen K; Haskell LP; Levine JG
    Gastroenterology; 1998 Sep; 115(3):525-32. PubMed ID: 9721148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: systemic and topical steroids in inflammatory bowel disease.
    Schölmerich J
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():66-74. PubMed ID: 15352897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: Drug development in inflammatory bowel disease: budesonide--a model of targeted therapy.
    Hamedani R; Feldman RD; Feagan BG
    Aliment Pharmacol Ther; 1997 Dec; 11 Suppl 3():98-107; discussion 107-8. PubMed ID: 9467984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.